Sun. Jun 16th, 2024
Andelyn Biosciences Collaborates with Grace Science to Further Develop GS-100

Grace Science LLC has partnered with Andelyn Biosciences Inc., a cell and gene therapy Contract Development and Manufacturing Organization (CDMO), to transfer technology and manufacture GS-100. GS-100 is a suspension process AAV NGLY1 gene therapy intended for Phase I/II/III clinical trial material aimed at treating NGLY1 Deficiency, a serious and life-threatening disease without any approved therapy currently available.

NGLY1 Deficiency is a debilitating condition that afflicts patients with life-long symptoms. The collaboration between Andelyn Biosciences and Grace Science seeks to increase program efficiency, support ongoing clinical trials, and expedite the availability of this crucial therapy to patients in need.

In 2021, GS-100 received orphan drug designation (ODD) from the FDA and the European Medicine Agency (EMA). The FDA also granted Rare Pediatric Disease Designation to GS-100 in 2021, potentially leading to a Priority Review Voucher upon approval for marketing and a Fast-Track designation in 2023. Grace Science successfully administered the first dose of GS-100 to an NGLY1 Deficiency patient in February of this year and plans to treat a second patient in May 2024.

Through this partnership, Grace Science will leverage Andelyn’s expertise in AAV processes and capabilities in late-stage manufacturing and commercial readiness to expedite its manufacturing timelines, offering hope to patients with NGLY1 Deficiency.

Matt Wilsey, CEO and Co-Founder of Grace Science, expressed his excitement about the partnership with Andelyn Biosciences. He noted that Andelyn’s expertise and experience in AAV gene therapy manufacturing would ensure that NGLY1 patients receive safe, high-quality drug products for clinical trials and beyond. Matt Niloff, Chief Commercial Officer at Andelyn Biosciences, echoed Wilsey’s sentiments by emphasizing their shared values of strong collaboration, customer-centric focus, and a quality-first mindset.

By Aiden Nguyen

As a content writer at newscholarly.com, I delve into the realms of storytelling with the power of words. With a knack for research and a passion for crafting compelling narratives, I strive to bring forth engaging and informative articles for our readers. From decoding complex concepts to unraveling current events, I aim to captivate and educate through the art of writing. Join me on this journey as we explore the ever-evolving landscape of news and knowledge together.

Leave a Reply